유방암 시장 - 삼중 음성 - KOL 인사이트

What's exciting oncologists in triple-negative cancer therapy? What clinical benefits do KOLs cite for AstraZeneca/Daiichi Sankyo's pipeline datopotamab deruxtecan and why will the readouts of the BEGONIA trial be significant? Why do experts believe the mechanism of action of G1 Therapeutics' late-stage CDK4/CDK6 inhibitor Cosela could lead to improved outcomes? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and KOL Bulletins via the attachments area.

Table of Contents

Executive summary

Triple-negative breast cancer current and future treatment algorithm

Research objectives

Triple-negative breast cancer

• Marketed drugs
  • Lynparza (olaparib; AstraZeneca/Merck & Co.)
  • Talzenna (talazoparib; Pfizer)
  • Tecentriq (atezolizumab; Roche)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Trodelvy (sacituzumab govitecan; Gilead Sciences)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
• Pipeline drugs
  • Bavencio (avelumab; Merck Group)
  • veliparib (ABT-888; AbbVie)
  • Zejula (niraparib; GlaxoSmithKline)
  • ipatasertib (Roche) and capivasertib (AstraZeneca)
  • Piqray (alpelisib; Novartis)
  • Cosela (trilaciclib; G1 Therapeutics)
  • datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo)
• General future trends impacting treatment
  • Key insights summary

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe